Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials

Large cardiovascular and kidney outcome trials have proven that most members of sodium glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are effective in reducing critical cardiorenal events in type 2 diabetic adults. However, the relative efficacy of different SGLT2 inhibitors and GLP-1 RAs in reducing cardiorenal events in type 2 diabetes is unclear. To our knowledge, identifying the most efficacious drugs is meaningful for the prevention of cardiorenal events in type 2 diabetes.
Source: Primary Care Diabetes - Category: Primary Care Authors: Tags: Brief report Source Type: research